Magazine Article | July 1, 2021

Companies To Watch: NervGen Pharma

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Beyond preclinicals to human trials: a drug that could repair and regrow neurons

SNAPSHOT

NervGen Pharma is a public company in Canada developing drugs to repair nerve damage and neurodegeneration by inhibiting protein tyrosine phosphatase sigma (PTP σ), a key component of the neural-death cascade, to promote nerve regeneration, remyelination, and increased neuroplasticity. Its lead product, coded NVG-291, is a peptide mimetic compound with wide potential for treating numerous neurological conditions. NVG-291 is about to enter a Phase 1 dose-escalation trial prior to planned clinical development for spinal-cord injury, MS, and Alzheimer’s disease.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: